- Home
- NXTC vs TRIB Comparison
NXTC vs TRIB Comparison
Compare NXTC & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- TRIB
- Stock Information
- Founded
- NXTC 2015
- TRIB 1992
- Country
- NXTC United States
- TRIB Ireland
- Employees
- NXTC N/A
- TRIB N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NXTC Health Care
- TRIB Health Care
- Exchange
- NXTC Nasdaq
- TRIB Nasdaq
- Market Cap
- NXTC 9.3M
- TRIB 10.7M
- IPO Year
- NXTC 2019
- TRIB N/A
- Fundamental
- Price
- NXTC $0.41
- TRIB $0.84
- Analyst Decision
- NXTC Strong Buy
- TRIB
- Analyst Count
- NXTC 2
- TRIB 0
- Target Price
- NXTC $3.50
- TRIB N/A
- AVG Volume (30 Days)
- NXTC 178.3K
- TRIB 73.0K
- Earning Date
- NXTC 05-01-2025
- TRIB 05-27-2025
- Dividend Yield
- NXTC N/A
- TRIB N/A
- EPS Growth
- NXTC N/A
- TRIB N/A
- EPS
- NXTC N/A
- TRIB N/A
- Revenue
- NXTC N/A
- TRIB $59,126,000.00
- Revenue This Year
- NXTC N/A
- TRIB $11.63
- Revenue Next Year
- NXTC N/A
- TRIB $10.13
- P/E Ratio
- NXTC N/A
- TRIB N/A
- Revenue Growth
- NXTC N/A
- TRIB N/A
- 52 Week Low
- NXTC $0.22
- TRIB $0.48
- 52 Week High
- NXTC $1.82
- TRIB $3.55
- Technical
- Relative Strength Index (RSI)
- NXTC 45.41
- TRIB 64.93
- Support Level
- NXTC $0.34
- TRIB $0.71
- Resistance Level
- NXTC $0.47
- TRIB $0.84
- Average True Range (ATR)
- NXTC 0.06
- TRIB 0.06
- MACD
- NXTC 0.01
- TRIB 0.00
- Stochastic Oscillator
- NXTC 39.66
- TRIB 74.24
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.